In this context, the integration of renin–angiotensin system inhibitors (RASi), which have previously demonstrated a pivotal role in managing diabetic kidney disease (DKD), with drugs possessing more targeted antidiabetic properties, such as SGLT2 inhibitors and glucagon-like peptide 1 (GLP1) antagonists, have been observed. Here, GLP1R is linked to diabetic kidney disease.